利拉鲁肽联合瑞格列奈治疗2型糖尿病的效果分析

Effect Analysis of Liraglutide Combined with Repaglinide in Treatment of Type 2 Diabetes Mellitus

目的:探讨利拉鲁肽联合瑞格列奈治疗2型糖尿病的临床效果。方法:选取2021年2-8月顺义区李遂镇卫生院收治的2型糖尿病患者30例为对照组,选取2021年4-9月顺义区李遂镇卫生院收治的2型糖尿病患者30例为观察组。对照组在降压、降脂基础上给予瑞格列奈治疗,观察组在对照组基础上给予利拉鲁肽治疗。比较两组患者血糖指标、炎性指标、血脂水平及体重指数(BMI)变化情况。结果:治疗后,两组患者空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)水平均下降,观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组患者超敏C反应蛋白(hs-CRP)、白介素-1B(IL-1B)、肿瘤坏死因子-α(TNF-α)水平均下降,观察组各指标水平低于对照组,差异有统计学意义(P<0.05);治疗后,两组患者低密度脂蛋白、甘油三酯水平均降低,高密度脂蛋白水平升高,观察组低密度脂蛋白、甘油三酯水平低于对照组,高密度脂蛋白水平高于对照组,差异均有统计学意义(P<0.05)。结论:利拉鲁肽联合瑞格列奈治疗2型糖尿病可以迅速降低血糖水平,减少炎性反应,改善血脂水平。

Objective: To investigate the clinical effect of liraglutide combined with repaglinide in the treatment of type 2 diabetes mellitus. Methods: Thirty patients with type 2 diabetes mellitus treated in Shunyi District Lisui Town Health Center from February to August in 2021 were collected as control group, and another 30 patients with type 2 diabetes mellitus treated in Shunyi District Lisui Town Health Center from April to September in 2021 were collected as observation group. In the control group, on the basis of hypotensive and lipid-lowering therapy, repaglinide was given;in the observation group, liraglutide was given on the basis of control group. The changes in blood glucose index, inflammatory index, blood lipid level and body mass index(BMI) of the two groups were compared. Results: After treatment, the levels of fasting blood glucose(FPG), 2 h postprandial blood glucose(2 hPG)and glycated hemoglobin(HbAlc) decreased in two groups, and the observation group was lower than the control group, with statistically significant differences(P<0.05). After treatment, the levels of hypersensitive C-reactive protein(hs-CRP), interleukin-1B(IL-1B) and tumor necrosis factor-α(TNF-α) decreased in two groups, and the observation group was lower than the control group, with statistically significant differences(P<0.05). After treatment, the levels of low-density lipoprotein and triglycerides in two groups were reduced, and the levels of high-density lipoprotein were increased, while the levels of low-density lipoprotein and triglycerides in the observation group were lower than those in the control group, and the levels of high-density lipoprotein were higher than those in the control group, with statistically significant differences(P<0.05). Conclusion: Liraglutide combined with repaglinide in the treatment of type 2 diabetes mellitus can rapidly reduce blood glucose level, decrease inflammatory reaction and improve blood lipid level.